Skip to content
MMR Sign In Subscribe
Pharmacy — Supplier News

Aurobindo gets FDA approval for dutasteride and tamsulosin hydrochloride capsules

EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for dutasteride and tamsulosin hydrochloride capsules 0.5 mg/0.4 mg.

,   and  Bill Schiffner
1 min read

EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for dutasteride and tamsulosin hydrochloride capsules 0.5 mg/0.4 mg. Aurobindo Pharma’s, are an AB-rated generic equivalent to the reference listed drug (RLD), Jalyn  Capsules, manufactured by Waylis Therapeutics.

Dutasteride and tamsulosin hydrochloride capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

Dutasteride and tamsulosin hydrochloride capsules has an estimated market size of US $9 Million for the twelve months ending May 2024, as per IQVIA.

Related

Latest

Retail shines despite exec exodus
Opinion

Retail shines despite exec exodus

David Pinto examines the growing wave of high-profile corporate executive retirements and departures reshaping leadership teams across major companies.

,   and  CDR
TSE reaffirmed its unique value
Opinion

TSE reaffirmed its unique value

By Mike Wysong, CEO of CARE Pharmacies Cooperative. In October 2026, the NACDS board elected Wysong its next president and CEO, succeeding Steven Anderson, who retires after twenty years.

,   and  CDR